Davis Polk partners David Bauer and Matt Bacal, counsel Samantha Lefland and law clerk Ted Talas authored “Artificial intelligence in drug development” in the Legal 500: Life Sciences Comparative Guide. In the chapter, they discuss the growth of the AI ecosystem in the pharmaceutical and biotechnology space as well as the legal and commercial risks and limitations relating to using AI in drug discovery and development.

Read the full chapter

Copy link to share post